AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has earned a consensus rating of “Hold” from the sixteen analysts that are presently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $25.25.

A number of research analysts recently commented on AMAG shares. BidaskClub upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Jefferies Group LLC set a $40.00 target price on shares of AMAG Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, April 20th. TheStreet cut shares of AMAG Pharmaceuticals from a “c” rating to a “d+” rating in a report on Friday, May 5th. Barclays PLC restated an “equal weight” rating and set a $20.00 target price (down from $25.00) on shares of AMAG Pharmaceuticals in a report on Thursday, June 1st. Finally, Deutsche Bank AG set a $24.00 target price on shares of AMAG Pharmaceuticals and gave the stock a “hold” rating in a report on Friday.

In other AMAG Pharmaceuticals news, SVP Julie Krop sold 1,891 shares of the business’s stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $24.45, for a total value of $46,234.95. Following the completion of the transaction, the senior vice president now directly owns 36,777 shares of the company’s stock, valued at $899,197.65. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 3.80% of the stock is currently owned by insiders.

Several institutional investors have recently made changes to their positions in the company. Skandinaviska Enskilda Banken AB publ increased its stake in AMAG Pharmaceuticals by 45.6% in the first quarter. Skandinaviska Enskilda Banken AB publ now owns 158,600 shares of the specialty pharmaceutical company’s stock worth $3,576,000 after buying an additional 49,700 shares during the period. Goldman Sachs Group Inc. increased its stake in AMAG Pharmaceuticals by 162.2% in the first quarter. Goldman Sachs Group Inc. now owns 607,980 shares of the specialty pharmaceutical company’s stock worth $13,710,000 after buying an additional 376,139 shares during the period. Credit Suisse AG increased its stake in AMAG Pharmaceuticals by 122.3% in the first quarter. Credit Suisse AG now owns 145,442 shares of the specialty pharmaceutical company’s stock worth $3,280,000 after buying an additional 80,011 shares during the period. Tudor Investment Corp ET AL increased its stake in AMAG Pharmaceuticals by 99.1% in the first quarter. Tudor Investment Corp ET AL now owns 22,300 shares of the specialty pharmaceutical company’s stock worth $503,000 after buying an additional 11,100 shares during the period. Finally, Jane Street Group LLC acquired a new stake in AMAG Pharmaceuticals during the first quarter worth $403,000.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/11/amag-pharmaceuticals-inc-nasdaqamag-receives-average-recommendation-of-hold-from-analysts.html.

Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) traded up 2.07% during midday trading on Tuesday, reaching $19.75. The company’s stock had a trading volume of 393,971 shares. The stock has a 50 day moving average of $18.02 and a 200-day moving average of $23.21. The company’s market capitalization is $692.14 million. AMAG Pharmaceuticals has a 1-year low of $16.00 and a 1-year high of $36.83.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Tuesday, May 2nd. The specialty pharmaceutical company reported ($1.06) EPS for the quarter, missing the Zacks’ consensus estimate of $0.09 by $1.15. AMAG Pharmaceuticals had a negative net margin of 5.61% and a positive return on equity of 1.69%. The company had revenue of $139.47 million for the quarter, compared to analyst estimates of $150.32 million. During the same quarter in the prior year, the business earned ($0.22) EPS. AMAG Pharmaceuticals’s revenue was up 27.6% compared to the same quarter last year. On average, equities research analysts anticipate that AMAG Pharmaceuticals will post $5.12 earnings per share for the current year.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.